Investigational drug · Phase 2
ALT001
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Ischemic Stroke in the Sequelae Stage, Amyotrophic Lateral Sclerosis (ALS).
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
5
Any phase or sponsor naming "ALT001"
First trial start
2026
Sep 1, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ALT001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Ischemic Stroke in the Sequelae Stage
- Amyotrophic Lateral Sclerosis (ALS)
Approved drugs for the same conditions: Stroke prevention · ALS (amyotrophic lateral sclerosis) · Cardiovascular and metabolic · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "ALT001" as an intervention, largest first.
- ALT001 in Patients With Ischemic Stroke in the Sequelae StagePivotal-lookingNot yet recruiting
Darwin Origin (Hubei) Biopharmaceutical Co., Ltd.Industry
NCT07841496 · 200 participants (planned) · Start Sep 21, 2026 · Primary completion Jun 30, 2027
Drug: ALT001 · For: Ischemic Stroke in the Sequelae Stage
Sites: Beijing, China
- A Phase II Study of ALT001 in Patients With Amyotrophic Lateral Sclerosis (ALS)Pivotal-lookingNot yet recruiting
Darwin Origin (Hubei) Biopharmaceutical Co., Ltd.Industry
NCT07833618 · 150 participants (planned) · Start Sep 1, 2026 · Primary completion Jan 1, 2028
Drug: ALT001 1.0 μg/kg; ALT001 2.0 μg/kg and 1 more · For: Amyotrophic Lateral Sclerosis (ALS)
Sites: Beijing, China
yilong WangAcademic, hospital or other
NCT07476352 · 60 participants (planned) · Start Jun 15, 2026 · Primary completion Oct 30, 2027
Drug: ALT001 · For: Multiple System Atrophy
Sites: Beijing, China
- Clinical Trial on the Efficacy and Safety of ALT001 in OsteoarthritisActive, not recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAcademic, hospital or other
NCT07404891 · 30 participants (planned) · Start Mar 18, 2026 · Primary completion Sep 17, 2026
Drug: ALT001 · For: Osteoarthritis
Sites: Wuhan, China
yilong WangAcademic, hospital or other
NCT07514923 · 20 participants (planned) · Start Jun 10, 2026 · Primary completion Jan 31, 2027
Drug: ALT001 · For: Multiple System Atrophy - Cerebellar Subtype (MSA-C)
Sites: Beijing, China · 2 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Allyl-substituted ALT001 promotes alternative mitophagy and improves therapeutic outcomes in Alzheimer's disease models.
Um JH, Choi SM, Kim YY, et al. · Sci Rep 2026
- A novel isoquinoline mitophagy inducer ameliorates paclitaxel-induced peripheral neuropathy in Drosophila and mouse models.
Im S, Choi SM, Kim YY, et al. · Sci Rep 2025
- Pharmacological targeting of mitophagy via ALT001 improves herpes simplex virus 1 (HSV1)-mediated microglial inflammation and promotes amyloid β phagocytosis by restricting HSV1 infection.
Oh SJ, Kim YY, Ma R, et al. · Theranostics 2025
- Selective induction of Rab9-dependent alternative mitophagy using a synthetic derivative of isoquinoline alleviates mitochondrial dysfunction and cognitive deficits in Alzheimer's disease models.
Um JH, Shin DJ, Choi SM, et al. · Theranostics 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.